Skip to content
Back to announcement

Financial Release Ytd Q3-2023.pdf

Financial statement Text extracted TSPC

Source file signed link, expires in 15 minutes

This browser can't display the PDF inline. Open it in a new tab.

Extracted text 5

Page 1 OCR 0.908
Ir

THE TEMPO GROUP

PT. Tempo Scan Pacific Tbk

Head Office : Tempo Scan Tower, 16" floor, Jl. H.R. Rasuna Said Kav. 3-4, Jakarta 12950, Indonesia
Phone : 2921 8888 Fax : 2920 9999 PO BOX : 3269 Jkt 10002 No. P-B.F. : 31081/PBFAN9A
Factory EJIP Industrial Park. Plot 1G-H, Lemahabang, Bekasi 17550 Phone : 897 1553, 8970801 Fax: 897 1563, 897 0764

Tempo Scan's YTD September 2023 Robust Results
Net Sales Grew By 7.456, Gross Profit Increased By 10.4X,

Operating Profit Grew By 15.3X & Net Profit Rose by 76.196

The Indonesian social and economic activities have fully returned back to normal, all
shopping malls, restaurants, stores and, air travels as well as large scale social
gatherings such as music concert, wedding, etc. have experienced robust growth.
Such a recovery served as the main catalyst for the Indonesia's economy to sustain
its growth despite the global economic turbulence, amongst other attributed to the
persistent interest rate hikes which triggering tight liguidity by world central banks
also due to various military and political conflicts in many parts of the world.

Almost similar with Indonesian economic growth pattern in 2022, whereas its economy
grew higher during 15! and 2”4 Ouarter 2023 by 5.03Yo and 5.176 respectively,
however subseguently it began to slowdown in 3"9 Guarter 2023 which is projected to
be around 4.8Yo. Such a pattern was influenced by the Household Consumptions which
has always been a major benefactor to the Indonesian economy given its 53,31Y6
contribution towards the country's GDP, while in 274 Guarter 2023 and it still grew by
5.23Yo. Such Household Consumptions increase had offset the country's export
revenue which had declined by 2.75Y6 in 2"4 Guarter 2023 amongst others due to
lower global commodities prices.

Given the above economic backdrop, Tempo Scan's net sales result for YTD
September 2023 grew by 7.4Yo and amounted to Rp.9,766.5 billion, and with
the full support of its majority shareholder, Tempo Scan continues to escalate its core
brand eguities marketing investment, on the other hand some of its key competitors
have reduced their marketing spending. Notwithstanding such investment, Tempo
Scan's operating profit managed to increase by 15.3Yo and amounted to
Rp.813.6 billion. While Tempo Scan's net profit after tax rose by 76.190 and
amounted to Rp.952.2 billion.

ia

Page | 1
Page 2 OCR 0.922
The abovementioned Tempo Scan's consolidated net sales result in YTD September
2023 main benefactors were:

1) Tempo Scan's Pharmaceutical division net sales performance remained
vigorous and able to sustain its turnaround, it grew double digits by
12.190 and amounted to Rp.2,971.9 billion, such net sales growth was higher
when compared to its growth in 18 Half 2023 whereas this division net sales grew
by only 11.996. The said Pharma division net sales performance was amongst other
boosted by its core brand eguities' continuous marketing investment.

This division net sales growth main benefactor continued to be its Consumer
Health products group which net sales increased significantly by 12.5Yo
and amounted to Rp.2,913.5 billion. This Consumer Health group's
commendable net sales increase was propelled by its Nutritional products' net
sales which has risen tremendously by 30.19Yo year on year. The said
Nutritional products robust growth was attributed by broad base consumers
demand increased in most of its major resellers and by wider geographical
distribution penetration especially outside Java island.

Whilst its Consumer Health group's OTC and Vitamins products' net sales have
increased by 2.0Y6o, such positive growth trajectory of these products' net sales
have solidified such products sales performance turnaround, amid the overall OTC
and Vitamins market weakness in general particularly post Covid-19 pandemic.
Therefore, Tempo Scan remains sanguine that such sales recovery trend can be
sustained leading to 2023 yearend closing.

The Prescription Medicines group's net sales performance remained sluggish and
it has declined by 4.896, its net sales amounted to a meager Rp.58.4 billion.
Correspondingly, in YTD September 2023 the Consumer Health products group
and the Prescription Medicines group net sales contributions toward the
Pharmaceutical division's total net sales were 98.0Yo and 2.0Yo.

Moreover, this division's international business net sales had increased by 9.246
and amounted to Rp.188,9 billion, commensurately the said international business
net sales contribution towards Tempo Scan's Pharmaceutical division total net sales
stood at 6.4Yo or slightly lower compared to its contribution of 6.5Y6 during the
same period last year.

Page | 2
Page 3 OCR 0.919
2) As pertained to Tempo Scan's Consumer Products & Cosmetics (“CPC”)
division was able to register a commendable net sales growth which
increased by 9.3”o and amounted to Rp.3,019.7 billion. This division's net
sales main benefactor continued to be its Consumer Products group which net
sales increased by 8.1Yo and amounted to Rp.2,426.1 billion. While its Cosmetics
group's net sales performance had continued to deliver an excellent growth with
an increase of 14.6Y6 and amounted to Rp.593.6 billion.

Conseguently, the Consumer Products group and Cosmetics group net sales
contributions toward Tempo Scan's CPC division's total net sales were 80.3Yo and
19.740 respectively in YTD September 2023 and marginally changed when
compared to their net sales contributions during YTD September 2022 which were
at 81.3Yo and 18.7Yo respectively.

During YTD September 2023, the CPC division's International Business maintained
its positive growth momentum following its initial turnaround commencing in the
1st Half 2022, and it registered a commendable double-digit net sales increase of
39.6Yo. Such a strong net sales performance was predominantly
contributed by its Consumer products and Cosmetics which net sales
have increased by 9.470 and 49.5Y6o respectively.

3) Tempo Scan's Distribution division continued its positive performance by growing
at 2.7Yo and amounted to Rp.3,774.9 billion. its main contributor of this division
net sales growth was its Non-Pharma Principals' products which net sales rose by
4.6Yo and amounted to Rp.3,485.5 billion, while on the other hand this division
Pharma Principals' products registered a decline of 16.0Ys and amounted to
Rp.289.4 billion. Correspondingly, the aforesaid Non-Pharma Principals' products
and Pharma Principals' products net sales contributions toward the Distribution
division total net sales stood at 92.3Yo and 7.7Yo respectively.

Furthermore, YTD September 2023 Tempo Scan's gross profit also rose by
10.470 and amounted to Rp.3,383.6 billion, such an increase was higher
compared to its net sales growth, conseguently its gross profit margin had
increased to become 34.6Yo versus its gross profit margin in the same
period last year which was 33.740. Such margin increased was attributed to
declining key raw materials prices in line with the global market trend. Moreover, since
the beginning of 2023 Tempo Scan' has commenced commercial production of its dairy
spray drying manufacturing facility, such a facility substitutes Tempo Scan's base
powder milk which was previously imported from Australia and New Zealand, therefore
such facility can reduce significantly Tempo Scan's cost of goods sold for its infant
formula and children growing up milk.

Page | 3
Page 4 OCR 0.917
Moving on to Tempo Scan's total operating expenses in YTD September' 2023,
whereas its selling expenses and general administrative expenses ratios were 20.846
and 4.7Yo respectively, or lower compared with the same ratios in the corresponding
period last year which stood at 21.8Yo and 4.9Yo respectively. Correspondingly Tempo
Scan's total operating expenses in YTD September 2023 had increased by 9.0Yc and
amounted to Rp.2,570.0 billion, such an increase was attributed to its selling expenses
increase that grew by 2.7Yo and amounted to Rp.2,033.5 billion. On the other hand,
the company's general administrative expenses had increased by 3.0Y6 and amounted
to Rp.461.7 billion.

Moreover, in YTD September 2023 Tempo Scan'5 net other operating expenses has
registered a forex loss amounting to Rp.54.5 billion versus in YTD September 2022
wherein it recorded a forex gain amounted to Rp.79.0 billion, conseguentiy its net
other operating expenses amounted to Rp.74.9 billion. Such an amount was a sharp
contrast compared to Tempo Scan 5 net other operating income in the corresponding
period last year which amounted to Rp.69.9 billion.

Notwithstanding the above, Tempo Scan's operating profit managed to register
an increase of 15.3Yo and amounted to Rp.813.6 billion, however if the
aforesaid forex (unrealized) loss of Rp.54.5 billion to be excluded then
Tempo Scan's core operating profit would instead be amounted to Rp.868.1
billion or a sharp increase of 38.5Yo.

Furthermore, its net non-operating income had increased significantly and amounted
to Rp.476.2 billion and it was mainly attributed to the one-time gain obtained from its
minority stake divestment to a third party of its associated company, which the
Company deemed no longer fit into its future strategic business roadmap. As the result,
Tempo Scan's YTD September 2023 net profit after tax has risen by 76.1Yo
and amounted to Rp.952.2 billion, conseguently its net profit after tax margin
stood at 9.7Yo or higher versus its net profit after tax margin in the same period last
year which was 5.996. Correspondingly Tempo Scan's EBITDA had also grown by
13.0Yo and amounted to Rp.1,058.5 billion, correspondingly its EBITDA
margin in YTD September 2023 was around 11.0”/o, compared to its EBITDA
margin of around 10.076 in the corresponding period last year.

Page | 4
Page 5 OCR 0.920
As pertained to Tempo Scan's balance sheet position in YTD September 2023, its cash
and cash eguivalent position remained solid, whereas it increased by 32.8Y6 year on
year and amounted to Rp.3,623.0 billion. In addition, its net operating cycle/NOC
stood at 72 days despite the difficult market condition versus its NOC in the
corresponding period last year which stood at 73 days. Moreover, in YTD September
2023 Tempo Scan's total assets was amounting to Rp.11,310.5 billion and
its shareholders eguities amounting to Rp.8,068.5 billion, as such
representing almost 6.6Yo and 12.4”/o increase respectively.

Tempo Scan's Board of Directors would like to express our highest appreciation to all
Tempo Scan's Board of Commissioners, its management team and all of its employees
for their continuous support, advise, dedication, commitment and hard works. As well
as to our valued shareholders, business partners, vendors, customers, and
professional parties that has made Tempo Scan can achieved the abovementioned
financial results.

Jakarta, 31 October 2023
On behalf of PT. Tempo Scan Pacific, Tbk.

Pa
"4

I le Dharma Wija
President Director

Copies:
- Mr. Handojo S. Muljadi, Tempo Scan's President Commissioner
- Tempo Scan's Board of Directors

Page | 5

File

File Open PDF
Source IDX
Size0.32 MB
Published1 Nov 2023
Pages5
Characters11,012
Text sourceOCR
OCR confidence0.917

Names mentioned 0 people and organisations named in the text · linked when the evidence is strong

The name pass has not read this document yet.

Extraction attempts how the parser did, and what it refused

Nothing structured was extracted from this document — the attempts below say why.

No extraction attempted yet.

Other files in this announcement 5

FinancialStatement-2023-III-TSPC.xlsx done
inlineXBRL.zip done
↑↓ select ↵ open ⇧↵ see every result